Despite Earnings Miss, Our Liquid Biopsy Play Gets the Good Housekeeping "Seal of Approval"

There's an old adage in business that I know you're familiar with: "You have to spend money to make money."

And after looking at the second-quarter earnings report of our "Liquid Biopsy" play, Trovagene Inc. (Nasdaq: TROV), that's exactly the force at work here.

The small-cap biotech firm reported a loss that was bigger than expected, and that sent shares down nearly 8% today.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK